Healthcare Industry News: continuous glucose monitor
News Release - February 7, 2006
Sontra Medical Introduces Generation 1.75 SonoPrep(R) Skin Permeation DeviceRolls Out New and Improved Ultrasonic Device for Topical Lidocaine Delivery
FRANKLIN, Mass., Feb. 7(HSMN NewsFeed)-- Sontra Medical Corporation (Nasdaq: SONT ) announced today that it has introduced its Generation 1.75 SonoPrep® skin permeation device for topical lidocaine delivery. The upgraded device has a new and improved ultrasonic hand piece and fluid delivery system that is much smaller, simpler and less expensive to manufacture. The new hand piece also will be incorporated into the 2nd generation SonoPrep skin permeation device scheduled to be introduced in May 2006. The 2nd Generation SonoPrep device is more portable with improved ergonomics, a replaceable battery, and a digital display that monitors operation. "The initial response from intravenous and pediatric nurses has been very positive," stated Barry Marston, Sontra's Vice President of Sales and Marketing. "The practitioners appreciate the smaller, more ergonomic hand piece that is easier to apply and more comfortable for the patients."
The SonoPrep ultrasonic skin permeation employs low frequency ultrasound to penetrate the skin's outermost layer, the stratum corneum. This simple and fast (average 15 second) treatment creates an imperceptible window through the skin that enables molecules to pass through with 100 times greater efficiency than intact skin. The SonoPrep ultrasonic skin permeation device makes the skin permeable for up to twenty-four hours for continuous non-invasive diagnostics such as glucose monitoring and transdermal drug delivery.
About Sontra Medical Corporation (http://www.sontra.com)
Sontra Medical Corporation is a technology leader in transdermal science. Sontra's SonoPrep ultrasound-mediated skin permeation technology combined with technical competencies in transdermal drug formulation, delivery systems and biosensors is creating a new paradigm in transdermal drug delivery and diagnosis. The SonoPrep technology is being developed for several billion dollar market opportunities, including continuous glucose monitoring and the transdermal delivery of large molecule drugs and vaccines. Sontra is currently marketing the SonoPrep device and procedure tray for use with topical lidocaine to achieve rapid (within five minutes) skin anesthesia.
Sean Moran, Sontra Medical CFO
SonoPrep is a registered trademark of Sontra Medical Corporation. All other company, product or service names mentioned herein are the trademarks or registered trademarks of their respective owners.
This press release contains forward-looking statements, which address a variety of subjects including, for example, the expected technological advances and availability of the second-generation SonoPrep device, the expected benefits and efficacy of the SonoPrep device in connection with diagnostics, vaccine delivery, glucose monitoring and transdermal drug delivery, Sontra's expected ability to develop, market and sell products based on its technology; the expected market opportunities, distribution and market acceptance of the SonoPrep device and technology, and Sontra's business, research, product development, regulatory approval, marketing and distribution plans and strategies. Statements that are not historical facts, including statements about our beliefs and expectations, are forward-looking statements. Such statements are based on our current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward- looking statements: our technology is new and we may experience adverse results in research and development efforts, product development, clinical trials, product evaluations, commercialization efforts, product distribution and market acceptance; markets for our products may develop slower than expected, or not at all; our sales cycle is lengthy and we are still developing sales and marketing strategies which may or may not prove effective; the SonoPrep device may not prove effective in connection with diagnostics, vaccine delivery, glucose monitoring and/or transdermal drug delivery; we may experience difficulties or delays in obtaining regulatory approvals to market products resulting from development efforts or difficulties or delays associated with sources of regulatory-approved transdermal drugs and vaccines; failure to obtain and maintain patent protection for discoveries or commercial limitations imposed by patents owned or controlled by third parties would have an adverse effect on us; we depend upon strategic partners and third-party distributors to develop, commercialize, market and sell products based on our work; and we require substantial additional funding to conduct research and development and to expand commercialization, distribution and marketing activities. For detailed information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to Sontra's filings with the Securities and Exchange Commission, including Sontra's most recent Quarterly Report on Form 10-QSB. Forward-looking statements represent management's current expectations and are inherently uncertain. We do not undertake any obligation to update forward-looking statements made by us.
Source: Sontra Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.